Avadel PharmaceuticalsAVDL
13F holders, Q2 2025 (June 30)3holders
0new positions
0sold out
$8.85avg. 13F price*
At the end of Q2 2025, 3 institutions reported holding Avadel Pharmaceuticals plc (AVDL) in their 13F filings, unchanged from Q1 2025. 0 opened new positions and 0 sold out. The largest holders were Knoll Capital Management, LLC ($5.3M), Schulhoff & Co. Inc. ($1.2M) and Huntington National Bank ($16).
- Company
- Avadel Pharmaceuticals plc
- CUSIP
- 05337M104
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2025 → Q2 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 0 | $0 |
Ownership 3 holders
| Knoll Capital Management, LLC | 3.78% | No change | 600,000 | $5.3M |
| Schulhoff & Co. Inc. | 0.54% | No change | 137,500 | $1.2M |
| Huntington National Bank | 0.00% | No change | 1 | $16 |
"% of holder's portfolio" is AVDL's weight in each manager's 13F, not the share of Avadel Pharmaceuticals plc the manager owns.